Condition
CD40 Ligand Deficiency
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Active Not Recruiting1
Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07284641Phase 2Recruiting
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
NCT01652092Not ApplicableActive Not Recruiting
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
NCT03333486Phase 2Terminated
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Showing all 3 trials